Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 11/20 | 0.51 |
| ▸ | COASY | Q13057 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5695181 | 0.98 | LCK (0.50) | LCKCOASYEGFRSRCZAP70 | |
| SCHEMBL5695226 | 0.82 | LCK (0.57) | LCKEGFRSRCZAP70MAOB | |
| SCHEMBL5695236 | 0.82 | LCK (0.51) | LCKEGFRSRCZAP70MAOB | |
| Hydrochloric Acid SCHEMBL6497662 | 0.81 | LCK (0.50) | LCKEGFRSRCZAP70MAOB | |
| SCHEMBL13238000 | 0.79 | COASY (0.46) | LCKCOASYEGFRSRCZAP70 | |
| SCHEMBL5695257 | 0.77 | LCK (0.54) | LCKEGFRSRCZAP70MAOB | |
| SCHEMBL1360450 | 0.76 | NPC1 (0.54) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL6492502 | 0.75 | LCK (0.53) | LCKEGFRSRCZAP70ADRA2A | |
| Hydrochloric Acid SCHEMBL5695191 | 0.75 | NPC1 (0.53) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL5695269 | 0.75 | PLAU (0.47) | LCKEGFRSRCZAP70ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341770-B1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-06-14 | — | — | EP | claimed |
| US-6686384-B2 | 2-ANILINOPHENYL-SUBSTITUTED; INHIBITION OF THE NA+/H+ EXCHANGER | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-03 | — | — | US | claimed |
| US-20030191170-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-10-09 | — | — | US | claimed |
| EP-1341770-A1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2003-09-10 | — | — | EP | claimed |
| US-20020132842-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | US | claimed |
| WO-2002046169-A1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-13 | — | — | WO | claimed |
| EP-1341770-B1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-06-14 | — | — | EP | disclosed |
| US-6958357-B2 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-10-25 | — | — | US | disclosed |
| US-6686384-B2 | 2-ANILINOPHENYL-SUBSTITUTED; INHIBITION OF THE NA+/H+ EXCHANGER | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-03 | — | — | US | disclosed |
| US-20030191170-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-10-09 | — | — | US | disclosed |
| EP-1341770-A1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2003-09-10 | — | — | EP | disclosed |
| US-20020132842-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | US | disclosed |
| WO-2002046169-A1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191170-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | ABCB11, ATP1A2, ATP1A1 | LCK 4175/4885COASY 3094/4885EGFR 3615/4885 |
| US-20020132842-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | ABCB11, ATP1A2, ATP1A1 | LCK 4175/4885COASY 3094/4885EGFR 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.